杜皮鲁玛
医学
特应性皮炎
安慰剂
皮肤病科
Janus激酶1
Janus激酶抑制剂
单克隆抗体
贾纳斯激酶
单克隆
药理学
受体
免疫学
内科学
抗体
替代医学
病理
作者
Thomas Bieber,Eric L. Simpson,Jonathan I. Silverberg,Diamant Thaçi,C. Paul,Andrew Pink,Yoko Kataoka,Chia‐Yu Chu,Marco DiBonaventura,Ricardo Rojo,Jeremias Antinew,Ileana A. Ionita,Rodney Sinclair,Seth Forman,Jacek Zdybski,Pinaki Biswas,Bimal Malhotra,Fan Zhang,Hernán Valdez
标识
DOI:10.1056/nejmoa2019380
摘要
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited.
科研通智能强力驱动
Strongly Powered by AbleSci AI